Natural killer (NK) cells and natural killer T (NKT) cells are subsets of lymphocytes that share
some phenotypical and functional similarities. Both cell types can rapidly respond to the …

For over 60 years, hematopoietic stem cell transplantation has been the major curative
therapy for several hematological and genetic disorders, but its efficacy is limited by the …

Graft-versus-host disease (GVHD) is the most important complication of allogeneic
hematopoietic stem cell transplantation (alloHSCT). We performed a prospective …

The field of hematopoietic stem cell transplant (HSCT) has made ground-breaking progress
in the treatment of many malignant and nonmalignant conditions. It has also pioneered the …

After more than 60 years of research in allogeneic hematopoietic cell transplantation (HCT),
this therapy has advanced from one that was declared dead in the 1960s to a standard …

Toxicities have limited the use of allogeneic hematopoietic cell transplantation (HCT) to
younger, medically fit patients. In a canine HCT model, a combination of postgrafting …

Allogeneic hematopoietic stem cell transplantation (HSCT) has evolved into an effective
adoptive cellular immunotherapy for the treatment of a number of cancers. The …

Cyclophosphamide (Cy) is a potent immunosuppressive agent that is selectively toxic to
lymphocytes proliferating in response to recent antigen stimulation. In animal models, both …

The ability of allogeneic bone-marrow cells and peripheral-blood stem cells to cure
leukaemia remains the most striking example of the ability of the human immune system to …

Many patients who require allogeneic hematopoietic stem cell transplantation (allo-HSCT)
lack a human leukocyte antigen (HLA)-matched donor. Here, we report a protocol for …